Articles

Videos

Podcasts

Clinical

Promising investigational oncology drugs include oral taxanes, small molecule drugs, and immunotherapies. 

Oncology Investigational Drug Developments Remain Promising, Despite Impact of COVID-19 Pandemic on Clinical Trials

Common factors that contributed to reported increased dissatisfaction at work include role conflict, quantity of work, workflow disruptions, organizational culture, and leadership support.

Hematology/Oncology Pharmacists Report Experiencing High Levels of Burnout

Even while therapeutically anticoagulated, patients with cancer have risk factors for recurring venous thromboembolism and bleeding, according to a session at the Hematology/Oncology Pharmacy Association 2021 Virtual Annual Conference. 

Prophylactic Approach to Cancer-Related Thrombosis May Be Optimal

During the initial CAR T-cell therapy period, the total cost of care ranged from $350,000 to more than $2 million.

Study Finds Total Cost of Care for CAR-T, Post-Treatment Events Can Exceed $1 Million

In a presentation at the Community Oncology Alliance 2021 Virtual Conference, Jeff Sharman, MD, summarized the most important developments in care for CLL.

Novel Treatments for Chronic Lymphocytic Leukemia Result in Improved Outcomes, Lower Adverse Effects

The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program immediately after their diagnosis had, on average, 70% less chance of having lingering leukemia cells after a month of chemotherapy than those not on the diet-and-exercise regimen.

Study: Mild Diet, Exercise Improves Survival for Young People With Leukemia

According to previous studies, youth who are obese when they begin chemotherapy are more than twice as likely to have remaining cancer cells after 1 month of treatment compared to their lean counterparts.

Diet, Exercise With Chemotherapy Leads to Increased Survival in Youth With Leukemia

As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape. 

HOPA 2021: Investigational Oncology Drugs Could Have Significant Impact on Patients

Isatuximab in combination with carfilzomib and dexamethasone reduced the risk of disease progression or death by 45% versus standard of care alone.

Isatuximab Granted FDA Approval for Relapsed, Refractory Multiple Myeloma

Although pediatric patients represent a small portion of total acute myeloid leukemia cases, clinicians said there is a critical need for more effective therapies in this population.